Platelet Immunology and Alloimmunization

Rossi's Principles of Transfusion Medicine: Fourth Edition

Volumn , Issue , 2009, Pages 168-186

  Curtis, Brian R ^a   McFarland, Janice G ^a  

^a BLOOD RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77949451756     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781444303513.ch11     Document Type: Chapter

References (157)

1. Lalezari P, Driscoll AM. Ability of thrombocytes to acquire HLA specificity from plasma. Blood 1982;59:167-70.
2. Santoso S, Mueller-Eckhardt G, Kiefel V, Mueller-Eckhardt C. HLA antigens on platelet membranes. In vitro and in vivo studies. Vox Sang 1986;51:327-33.
3. Kao KJ. Selective elution of HLA antigens and beta 2-microglobulin from human platelets by chloroquine diphosphate. Transfusion 1988;28:14-17.
4. Sugawara S, Abo T, Kumagai K. A simple method to eliminate the antigenicity of surface class I MHC molecules from the membrane of viable cells by acid treatment at pH 3. J Immunol Methods 1987;100:83-90.
5. Neumuller J, Tohidast-Akrad M, Fischer M, Mayr WR. Influence of chloroquine or acid treatment of human platelets on the antigenicity of HLA and the 'thrombocyte-specific' glycoproteins Ia/IIa, IIb, and Ilb/IIIa. Vox Sang 1993;65:223-31.
6. Gouttefangeas C, Diehl M, Keilholz W, et al. Thrombocyte HLA molecules retain nonrenewable endogenous peptides of megakaryocyte lineage and do not stimulate direct allocytotoxicity in vitro. Blood 2000;95:3168-75.
7. Feuerstein N, Monos DS, Cooper HL. Phorbol ester effect in platelets, lymphocytes, and leukemic cells (HL-60) is associated with enhanced phosphorylation of class I HLA antigens. Coprecipitation of myosin light chain. Biochem Biophys Res Commun 1985;126:206-13.
8. Santoso S, Kalb R, Kiefel V, Mueller-Eckhardt C. The presence of messenger RNA for HLA class I in human platelets and its capability for protein biosynthesis. Br J Haematol 1993;84:451-6.
9. Janson M, McFarland J, Aster RH. Quantitative determination of platelet surface alloantigens using a monoclonal probe. Hum Immunol 1986;15:251-62.
10. Kao KJ, Cook DJ, Scornik JC. Quantitative analysis of platelet surface HLA by W6/32 anti-HLA monoclonal antibody. Blood 1986;68:627-32.
11. Pereira J, Cretney C, Aster RH. Variation of class I HLA antigen expression among platelet density cohorts: A possible index of platelet age? Blood 1988;71:516-19.
12. Kao KJ, Scornik JC, McQueen CF. Evaluation of individual specificities of class I HLA on platelets by a newly developed monoclonal antibody. Hum Immunol 1990;27:285-97.
13. Szatkowski NS, Aster RH. HLA antigens of platelets. IV. Influence of "private" HLA-B locus specificities on the expression of Bw4 and Bw6 on human platelets. Tissue Antigens 1980;15:361-8.
14. Datema G, Stein S, Eijsink C, et al. HLA-C expression on platelets: Studies with an HLA-Cw1-specific human monoclonal antibody. Vox Sang 2000;79:108-11.
15. Mueller-Eckhardt G, Hauck M, Kayser W, Mueller-Eckhardt C. HLA-C antigens on platelets. Tissue Antigens 1980;16:91-4.
16. Boshkov LK, Kelton JG, Halloran PF. HLA-DR expression by platelets in acute idiopathic thrombocytopenic purpura. Br J Haematol 1992;81:552-7.
17. Dunstan RA, Simpson MB. Heterogeneous distribution of antigens on human platelets demonstrated by fluorescence flow cytometry. Br J Haematol 1985;61:603-9.
18. Aster RH. Effect of anticoagulant and ABO incompatibility on recovery of transfused human platelets. Blood 1965;26:732-43.
19. Curtis BR, Edwards JT, Hessner MJ, et al. Blood group A and B antigens are strongly expressed on platelets of some individuals. Blood 2000;96:1574-81.
20. Ogasawara K, Ueki J, Takenaka M, Furihata K. Study on the expression of ABH antigens on platelets. Blood 1993;82:993-9.
21. Santoso S, Kiefel V, Mueller-Eckhardt C. Blood group A and B determinants are expressed on platelet glycoproteins IIa, IIIa, and Ib. Thromb Haemost 1991;65:196-201.
22. 2 individuals. Transfusion 1988;28:456-9.
23. Kelton JG, Hamid C, Aker S, Blajchman MA. The amount of blood group A substance on platelets is proportional to the amount in the plasma. Blood 1982;59:980-5.
24. Dunstan RA, Simpson MB, Knowles RW, Rosse WF. The origin of ABH antigens on human platelets. Blood 1985;65:615-19.
25. Curtis BR, Aster RH. Expression of ABH antigens on platelets (letter). Blood 2006;107:842. [see author reply 2006;107:842-3.]
26. Mollicone R, Caillard T, Le Pendu J, et al. Expression of ABH and X (Lex) antigens on platelets and lymphocytes. Blood 1988;71:1113-19.
27. Stockelberg D, Hou M, Rydberg L, et al. Evidence for an expression of blood group A antigen on platelet glycoproteins IV and V. Transfus Med 1996;6:243-8.
28. Kelton JG, Smith JW, Horsewood P, et al. ABH antigens on human platelets: Expression on the glycosyl phosphatidylinositol-anchored protein CD109. J Lab Clin Med 1998;132:142-8.
29. Curtis BR, Fick A, Lochowicz AJ, et al. Neonatal alloimmune thrombocytopenia associated with maternal-fetal incompatibility for blood group B. Transfusion 2008;48:358-64.
30. Dunstan RA, Simpson MB, Rosse WF. Erythrocyte antigens on human platelets. Absence of Rh, Duffy, Kell, Kidd, and Lutheran antigens. Transfusion 1984;24:243-6.
31. Greenwalt DE, Lipsky RH, Ockenhouse CF, et al. Membrane glycoprotein CD36: A review of its roles in adherence, signal transduction, and transfusion medicine. Blood 1992;80:1105-15.
32. Podrez EA, Byzova TV, Febbraio M, et al. Platelet CD36 links hyperlipidemia, oxidant stress and a prothrombotic phenotype. Nat Med 2007;13:1086-95.
33. Yanai H, Chiba H, Fujiwara H, et al. Phenotype-genotype correlation in CD36 deficiency types I and II. Thromb Haemost 2000;84:436-41.
34. a, involved in the refractoriness of HLA-matched platelet transfusion. Vox Sang 1989;57:213-17.
35. Curtis BR, Aster RH. Incidence of the Nak(a)-negative platelet phenotype in African Americans is similar to that of Asians. Transfusion 1996;36:331-4.
36. Lee K, Godeau B, Fromont P, et al. CD36 deficiency is frequent and can cause platelet immunization in Africans. Transfusion 1999;39:873-9.
37. Curtis BR, Ali S, Glazier AM, et al. Isoimmunization against CD36 (glycoprotein IV): Description of four cases of neonatal isoimmune thrombocytopenia and brief review of the literature. Transfusion 2002;42:1173-9.
38. Kashiwagi H, Tomiyama Y, Nozaki S, et al. Analyses of genetic abnormalities in type I CD36 deficiency in Japan: Identification and cell biological characterization of two novel mutations that cause CD36 deficiency in man. Hum Genet 2001;108:459-66.
39. Aitman TJ, Cooper LD, Norsworthy PJ, et al. Malaria susceptibility and CD36 mutation. Nature 2000;405:1015-16.
40. Curtis BR, Donnelly SF, Mintz PD, et al. Platelet transfusion refractoriness in a African American patient due to anti-Nak(a) (abstract). Transfusion 1997;37(Suppl):96S.
41. Beyer GM, Martin MA, Nash T, et al. Platelet refractoriness secondary to platelet-specific antibody against glycoprotein IV (CD36) (abstract). Transfusion 2007;47(Suppl):196A.
42. Broderick WR, Toor AA, Curtis BR, et al. Refractory thrombocytopenia due to allo-immune anti-CD36 complicating unrelated donor bone marrow transplant in a CD36-negative recipient(abstract). Blood 2007;110(Suppl): 4651b.
43. a) isoimmunization. Transfusion 1995;35:777-82.
44. Kankirawatana S, Kupatawintu P, Juji T, et al. Neonatal alloimmune thrombocytopenia due to anti-Nak(a). Transfusion 2001;41:375-7.
45. Solomon KR, Sharma P, Chan M, et al. CD109 represents a novel branch of the alpha2-macroglobulin/complement gene family. Gene 2004;327:171-83.
46. Smith JW, Hayward CP, Horsewood P, et al. Characterization and localization of the Gova/b alloantigens to the glycosylphosphati- dylinositol-anchored protein CDw109 on human platelets. Blood 1995;86:2807-14.
47. Lin M, Sutherland DR, Horsfall W, et al. Cell surface antigen CD109 is a novel member of the alpha(2) macroglobulin/C3, C4, C5 family of thioester-containing proteins. Blood 2002;99:1683-91.
48. 703 polymorphism of CD109 defines the Gov platelet alloantigens. Blood 2002;99:1692-8.
49. Ertel K, Al-Tawil M, Santoso S, Kroll H. Relevance of the HPA-15 (Gov) polymorphism on CD109 in alloimmune thrombocytopenic syndromes. Transfusion 2005;45:366-73.
50. Mandelbaum M, Koren D, Eichelberger B, et al. Frequencies of maternal platelet alloantibodies and autoantibodies in suspected fetal/neonatal alloimmune thrombocytopenia, with emphasis on human platelet antigen-15 alloimmunization. Vox Sang 2005;89:39-43.
51. Berry JE, Murphy CM, Smith GA, et al. Detection of Gov system antibodies by MAIPA reveals an immunogenicity similar to the HPA-5 alloantigens. Br J Haematol 2000;110:735-42.
52. Metcalfe P, Watkins NA, Ouwehand WH, et al. Nomenclature of human platelet antigens. Vox Sang 2003;85:240-5.
53. Saito S, Ota S, Seshimo H, et al. Platelet transfusion refractoriness caused by a mismatch in HLA-C antigens. Transfusion 2002;42:302-8.
54. Howard JE, Perkins HA. The natural history of alloimmunization to platelets. Transfusion 1978;18:496-503.
55. Dutcher JP, Schiffer CA, Aisner J, Wiernik PH. Alloimmunization following platelet transfusion: The absence of a dose-response relationship. Blood 1981;57:395-8.
56. The Trial to Reduce Alloimmunization to Platelets Study Group. Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions. N Engl J Med 1997;337:1861-9.
57. Seftel MD, Growe GH, Petraszko T, et al. Universal prestorage leuko- reduction in Canada decreases platelet alloimmunization and refractoriness. Blood 2004;103:333-9.
58. Atlas E, Freedman J, Blanchette V, et al. Downregulation of the anti-HLA alloimmune response by variable region-reactive (antiidiotypic) antibodies in leukemic patients transfused with platelet concentrates. Blood 1993;81:538-42.
59. Meenaghan M, Judson PA, Yousaf K, et al. Antibodies to platelet glycoprotein V in polytransfused patients with haematological disease. Vox Sang 1993;64:167-70.
60. Godeau B, Fromont P, Seror T, et al. Platelet alloimmunization after multiple transfusions: A prospective study of 50 patients. Br J Haematol 1992;81:395-400.
61. Pamphilon DH, Farrell DH, Donaldson C, et al. Development of lymphocytotoxic and platelet-reactive antibodies: A prospective study in patients with acute leukaemia. Vox Sang 1989;57:177-81.
62. Murphy MF, Metcalfe P, Ord J, et al. Disappearance of HLA and platelet-specific antibodies in acute leukaemia patients alloimmu- nized by multiple transfusions. Br J Haematol 1987;67:255-60.
63. Sintnicolaas K, van Marwijk Kooij M, van Prooijen HC, et al. Leukocyte depletion of random single-donor platelet transfusions does not prevent secondary human leukocyte antigen-alloimmunization and refractoriness: A randomized prospective study. Blood 1995;85:824-8.
64. Novotny VM, van Doorn R, Witvliet MD, et al. Occurrence of allogeneic HLA and non-HLA antibodies after transfusion of prestorage filtered platelets and red blood cells: A prospective study. Blood 1995;85:1736-41. [See comment in 1995;86:3263-4.]
65. Lee EJ, Schiffer CA. Serial measurement of lymphocytotoxic antibody and response to nonmatched platelet transfusions in alloim- munized patients. Blood 1987;70:1727-9.
66. DeCoteau J, Haddad S, Blanchette V, Poon A. Refractoriness to platelet transfusions in children with acute leukemia. J Pediatr Hematol Oncol 1995;17:306-10.
67. Friedman DF, Lukas MB, Jawad A, et al. Alloimmunization to platelets in heavily transfused patients with sickle cell disease. Blood 1996;88:3216-22.
68. Lo SC, Chang JS, Lin SW, Lin DT. Platelet alloimmunization after long-term red cell transfusion in transfusion-dependent thalassemia patients. Transfusion 2005;45:761-5.
69. Taaning E, Simonsen AC, Hjelms E, et al. Platelet alloimmunization after transfusion. A prospective study in 117 heart surgery patients. Vox Sang 1997;72:238-41.
70. Moazami N, Itescu S, Williams MR, et al. Platelet transfusions are associated with the development of anti-major histocompatibility complex class I antibodies in patients with left ventricular assist support. J Heart Lung Transplant 1998;17:876-80.
71. Slichter SJ, O'Donnell MR, Weiden PL, et al. Canine platelet alloimmunization: The role of donor selection. Br J Haematol 1986;63:713-27.
72. Gmur J, von Felten A, Osterwalder B, et al. Delayed alloimmunization using random single donor platelet transfusions: A prospective study in thrombocytopenic patients with acute leukemia. Blood 1983;62:473-9.
73. Novotny VM. Prevention and management of platelet transfusion refractoriness. Vox Sang 1999;76:1-13.
74. Delaflor-Weiss E, Mintz PD. The evaluation and management of platelet refractoriness and alloimmunization. Transfus Med Rev 2000;14:180-96.
75. Dutcher JP, Schiffer CA, Aisner J, Wiernik PH. Long-term follow-up patients with leukemia receiving platelet transfusions: Identification of a large group of patients who do not become alloimmunized. Blood 1981;58:1007-11.
76. Hogge DE, Dutcher JP, Aisner J, Schiffer CA. Lymphocytotoxic antibody is a predictor of response to random donor platelet transfusion. Am J Hematol 1983;14:363-9.
77. McGrath K, Wolf M, Bishop J, et al. Transient platelet and HLA antibody formation in multitransfused patients with malignancy. Br J Haematol 1988;68:345-50.
78. Brand A, Claas FH, Voogt PJ, et al. Alloimmunization after leukocyte-depleted multiple random donor platelet transfusions. Vox Sang 1988;54:160-6.
79. Murphy MF, Metcalfe P, Thomas H, et al. Use of leucocyte-poor blood components and HLA-matched-platelet donors to prevent HLA alloimmunization. Br J Haematol 1986;62:529-34.
80. Eernisse JG, Brand A. Prevention of platelet refractoriness due to HLA antibodies by administration of leukocyte-poor blood components. Exp Hematol 1981;9:77-83.
81. Semple JW, Speck ER, Milev YP, et al. Indirect allorecognition of platelets by T helper cells during platelet transfusions correlates with anti-major histocompatibility complex antibody and cytotoxic T lymphocyte formation. Blood 1995;86:805-12.
82. Bordin JO, Bardossy L, Blajchman MA. Experimental animal model of refractoriness to donor platelets: The effect of plasma removal and the extent of white cell reduction on allogeneic alloimmunization. Transfusion 1993;33:798-801.
83. Ramos RR, Curtis BR, Duffy BF, Chaplin H. Low retention of white cell fragments by polyester fiber white cell-reduction platelet filters. Transfusion 1994;34:31-4.
84. Kickler T. Platelet-compatibility testing: An update. Lab Management 1987;1:33-9.
85. Kiefel V, Konig C, Kroll H, Santoso S. Platelet alloantibodies in transfused patients. Transfusion 2001;41:766-70.
86. A2) and multiple HLA antibodies. Transfusion 1988;28:597-600.
87. Taaning E, Jacobsen N, Morling N. Graft-derived anti-HPA-2b production after allogeneic bone-marrow transplantation. Br J Haematol 1994;86:651-3.
88. Murata M, Furihata K, Ishida F, et al. Genetic and structural characterization of an amino acid dimorphism in glycoprotein Ib alpha involved in platelet transfusion refractoriness. Blood 1992;79:3086-90.
89. a, involved in platelet transfusion refractoriness in a Japanese man. Vox Sang 1989;56:283-7.
90. Novotny VM, Doxiadis, II, Brand A. The reduction of HLA class I expression on platelets: A potential approach in the management of HLA-alloimmunized refractory patients. Transfus Med Rev 1999;13:95-105.
91. Duquesnoy RJ, Anderson AJ, Tomasulo PA, Aster RH. ABO compatibility and platelet transfusions of alloimmunized thrombocytopenic patients. Blood 1979;54:595-9.
92. Brand A, Sintnicolaas K, Claas FH, Eernisse JG. ABH antibodies causing platelet transfusion refractoriness. Transfusion 1986;26:463-6.
93. Heal JM, Rowe JM, McMican A, et al. The role of ABO matching in platelet transfusion. Eur J Haematol 1993;50:110-17.
94. Heal JM, Rowe JM, Blumberg N. ABO and platelet transfusion revisited. Ann Hematol 1993;66:309-14.
95. Carr R, Hutton JL, Jenkins JA, et al. Transfusion of ABO- mismatched platelets leads to early platelet refractoriness. Br J Haematol 1990;75:408-13.
96. Heal JM, Masel D, Blumberg N. Interaction of platelet Fc and complement receptors with circulating immune complexes involving the ABO system. Vox Sang 1996;71:205-11.
97. Heal JM, Cowles J, Masel D, et al. Antibodies to plasma proteins: An association with platelet transfusion refractoriness. Br J Haematol 1992;80:83-90.
98. Ohto H, Yasuda H, Abe R, et al. Platelet transfusion refractoriness associated with plasma proteins. Br J Haematol 1993;83:680-1.
99. Blumberg N, Heal JM, Hicks GL Jr. , Risher WH. Association of ABO-mismatched platelet transfusions with morbidity and mortality in cardiac surgery. Transfusion 2001;41:790-3.
100. Lin Y, Callum JL, Coovadia AS, Murphy PM. Transfusion of ABO- nonidentical platelets is not associated with adverse clinical outcomes in cardiovascular surgery patients. Transfusion 2002;42:166-72.
101. Cooling L. ABO and platelet transfusion therapy. Immunohematol 2007;23:20-33.
102. Slichter SJ. Algorithm for managing the platelet refractory patient. J Clin Apher 1997;12:4-9.
103. Benson K. Criteria for diagnosing refractoriness to platelet transfusions. In: Kickler TS, Herman JH, eds. Current issues in platelet transfusion therapy and platelet alloimmunity. Bethesda, MD: AABB Press, 1999:33-61.
104. Davis KB, Slichter SJ, Corash L. Corrected count increment and percent platelet recovery as measures of posttransfusion platelet response: Problems and a solution. Transfusion 1999;39:586-92.
105. Doughty HA, Murphy MF, Metcalfe P, et al. Relative importance of immune and non-immune causes of platelet refractoriness. Vox Sang 1994;66:200-5.
106. Bishop JF, McGrath K, Wolf MM, et al. Clinical factors influencing the efficacy of pooled platelet transfusions. Blood 1988;71:383-7.
107. Alcorta I, Pereira A, Ordinas A. Clinical and laboratory factors associated with platelet transfusion refractoriness: A case-control study. Br J Haematol 1996;93:220-4.
108. McFarland JG, Anderson AJ, Slichter SJ. Factors influencing the transfusion response to HLA-selected apheresis donor platelets in patients refractory to random platelet concentrates. Br J Haematol 1989;73:380-6.
109. Norol F, Kuentz M, Cordonnier C, et al. Influence of clinical status on the efficiency of stored platelet transfusion. Br J Haematol 1994;86:125-9.
110. Christie DJ, van Buren N, Lennon SS, Putnam JL. Vancomycin- dependent antibodies associated with thrombocytopenia and refractoriness to platelet transfusion in patients with leukemia. Blood 1990;75:518-23.
111. Von Drygalski A, Curtis BR, Bougie DW, et al. Vancomycin-induced immune thrombocytopenia. N Engl J Med 2007;356:904-10.
112. Hogge DE, McConnell M, Jacobson C, et al. Platelet refractoriness and alloimmunization in pediatric oncology and bone marrow transplant patients. Transfusion 1995;35:645-52.
113. Schiffer CA, Dutcher JP, Aisner J, et al. A randomized trial of leukocyte-depleted platelet transfusion to modify alloimmunization in patients with leukemia. Blood 1983;62:815-20.
114. Yankee RA, Grumet FC, Rogentine GN. Platelet transfusion. The selection of compatible platelet donors for refractory patients by lymphocyte HL-A typing. N Engl J Med 1969;281:1208-12.
115. Oldfather JW, Anderson CB, Phelan DL, et al. Prediction of crossmatch outcome in highly sensitized dialysis patients based on the identification of serum HLA antibodies. Transplantation 1986;42:267-70.
116. Duquesnoy RJ, Filip DJ, Rodey GE, et al. Successful transfusion of platelets "mismatched" for HLA antigens to alloimmunized thrombocytopenic patients. Am J Hematol 1977;2:219-26.
117. Jorgensen DW, McFarland JG, Hillman RS, Slichter SJ. Plateletapheresis program. II. Computer selection of HLA compatible donors. Transfusion 1984;24:292-8.
118. Engelfriet CP, Reesink HW, Aster RH, et al. Management of alloim- munized, refractory patients in need of platelet transfusions. Vox Sang 1997;73:191-8.
119. Bolgiano DC, Larson EB, Slichter SJ. A model to determine required pool size for HLA-typed community donor apheresis programs. Transfusion 1989;29:306-10.
120. Schiffer CA, O'Connell B, Lee EJ. Platelet transfusion therapy for alloimmunized patients: Selective mismatching for HLA B12, an antigen with variable expression on platelets. Blood 1989;74:1172-6.
121. Hussein MA, Lee EJ, Fletcher R, Schiffer CA. The effect of lym- phocytotoxic antibody reactivity on the results of single antigen mismatched platelet transfusions to alloimmunized patients. Blood 1996;87:3959-62.
122. Petz LD, Garratty G, Calhoun L, et al. Selecting donors of platelets for refractory patients on the basis of HLA antibody specificity. Transfusion 2000;40:1446-56.
123. Zimmermann R, Wittmann G, Zingsem J, et al. Antibodies to private and public HLA class I epitopes in platelet recipients. Transfusion 1999;39:772-80.
124. Kickler T, Kennedy SD, Braine HG. Alloimmunization to platelet- specific antigens on glycoproteins IIb-IIIa and Ib/IX in multiply transfused thrombocytopenic patients. Transfusion 1990;30:622-5.
125. Kekomaki S, Volin L, Koistinen P, et al. Successful treatment of platelet transfusion refractoriness: The use of platelet transfusions matched for both human leucocyte antigens (HLA) and human platelet alloantigens (HPA) in alloimmunized patients with leukaemia. Eur J Haematol 1998;60:112-18.
126. Kickler T. Pretransfusion testing for platelet transfusions. Transfusion 2000;40:1425-6.
127. Shibata Y, Juji T, Nishizawa Y, et al. Detection of platelet antibodies by a newly developed mixed agglutination with platelets. Vox Sang 1981;41:25-31.
128. Rachel JM, Sinor LT, Tawfik OW, et al. A solid-phase red cell adherence test for platelet cross-matching. Med Lab Sci 1985;42:194-5.
129. O'Connell BA, Schiffer CA. Donor selection for alloimmunized patients by platelet crossmatching of random-donor platelet concentrates. Transfusion 1990;30:314-17.
130. Friedberg RC, Donnelly SF, Mintz PD. Independent roles for platelet crossmatching and HLA in the selection of platelets for alloim- munized patients. Transfusion 1994;34:215-20.
131. Rachel JM, Summers TC, Sinor LT, Plapp FV. Use of a solid phase red blood cell adherence method for pretransfusion platelet compatibility testing. Am J Clin Pathol 1988;90:63-8.
132. Moroff G, Garratty G, Heal JM, et al. Selection of platelets for refractory patients by HLA matching and prospective crossmatching. Transfusion 1992;32:633-40.
133. Freedman J, Hooi C, Garvey MB. Prospective platelet crossmatching for selection of compatible random donors. Br J Haematol 1984;56:9-18.
134. Rebulla P, Morelati F, Revelli N, et al. Outcomes of an automated procedure for the selection of effective platelets for patients refractory to random donors based on cross-matching locally available platelet products. Br J Haematol 2004;125:83-9.
135. Murphy S, Varma M. Selecting platelets for transfusion of the alloimmunized patient: A review. Immunohematol 1998;14:117-23.
136. Kurz M, Knobl P, Kalhs P, et al. Platelet-reactive HLA antibodies associated with low posttransfusion platelet increments: A comparison between the monoclonal antibody-specific immobilization of platelet antigens assay and the lymphocytotoxicity test. Transfusion 2001;41:771-4.
137. Gebel HM, Bray RA. Sensitization and sensitivity: Defining the unsensitized patient. Transplantation 2000;69:1370-4.
138. Gelb AB, Leavitt AD. Crossmatch-compatible platelets improve corrected count increments in patients who are refractory to randomly selected platelets. Transfusion 1997;37:624-30.
139. Schiffer CA, Hogge DE, Aisner J, et al. High-dose intravenous gammaglobulin in alloimmunized platelet transfusion recipients. Blood 1984;64:937-40.
140. Kickler T, Braine HG, Piantadosi S, et al. A randomized, placebocontrolled trial of intravenous gammaglobulin in alloimmunized thrombocytopenic patients. Blood 1990;75:313-16.
141. Zeigler ZR, Shadduck RK, Rosenfeld CS, et al. Intravenous gamma globulin decreases platelet-associated IgG and improves transfusion responses in platelet refractory states. Am J Hematol 1991;38:15-23.
142. Heddle NM, Klama L, Kelton JG, et al. The use of anti-D to improve post-transfusion platelet response: A randomized trial. Br J Haematol 1995;89:163-8.
143. Wong PM, Hiruma K, Endoh N, et al. Vinblastine-loaded platelet transfusion in an alloimmunized patient. Br J Haematol 1987;65:380-1.
144. Tilly H, Azagury M, Bastit D, et al. Cyclosporin for treatment of life-threatening alloimmunization. Am J Hematol 1990;34:75-6.
145. Christie DJ, Howe RB, Lennon SS, Sauro SC. Treatment of refractoriness to platelet transfusion by protein A column therapy. Transfusion 1993;33:234-42.
146. Rock G. The application of protein A immunoadsorption to remove platelet alloantibodies. Transfusion 1993;33:192-4.
147. Chao FC, Kim BK, Houranieh AM, et al. Infusible platelet membrane microvesicles: A potential transfusion substitute for platelets. Transfusion 1996;36:536-42.
148. Vostal JG, Reid TJ, Mondoro TH. Summary of a workshop on in vivo efficacy of transfused platelet components and platelet substitutes. Transfusion 2000;40:742-50.
149. Ciurea SO, Hoffman R. Cytokines for the treatment of thrombocytopenia. Semin Hematol 2007;44:166-82.
150. Kuter DJ, Cebon J, Harker LA, et al. Platelet growth factors: Potential impact on transfusion medicine. Transfusion 1999;39:321-32.
151. Fanucchi M, Glaspy J, Crawford J, et al. Effects of polyethylene glycol-conjugated recombinant human megakaryocyte growth and development factor on platelet counts after chemotherapy for lung cancer. N Engl J Med 1997;336:404-9.
152. Meehan KR, Matias CO, Rathore SS, et al. Platelet transfusions: Utilization and associated costs in a tertiary care hospital. Am J Hematol 2000;64:251-6.
153. Lill M, Snider C, Calhoun L. Analysis of utilization and cost of platelet transfusions in refractory hematology/oncology patients (abstract). Transfusion 1997;37(Suppl):26S.
154. Ness PM, Campbell-Lee SA. Single donor versus pooled random donor platelet concentrates. Curr Opin Hematol 2001;8:392-6.
155. Pamphilon DH. The rationale and use of platelet concentrates irradiated with ultraviolet-B light. Transfus Med Rev 1999;13:323-33.
156. Kao KJ. A critical analysis of clinical trials to prevent platelet alloimmunization. In: Kickler TS, Herman JH, eds. Current issues in platelet transfusion therapy and platelet alloimmunity. Bethesda, MD: AABB Press, 1998:103-34.
157. Vamvakas EC. Meta-analysis of randomized controlled trials of the efficacy of white cell reduction in preventing HLA-alloimmu- nization and refractoriness to random-donor platelet transfusions. Transfus Med Rev 1998;12:258-70.